PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
| 1.5 | |
| 1.53 | |
| - | |
| 1.56 | |
| 1.49 | |
| 1.175-6.98 | |
| 77 280 K | |
| 51 520 K | |
| 0 | |
| -0.02 | |
| 1.518 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PMV Pharmaceuticals, Inc. Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and mar...
PMV Pharmaceuticals, Inc. PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Me...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
